Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Q2 Organic Revs Rise 8 Percent, Though Receipts Slide for Second Consecutive Sequential Period

Bruker's revenues have slid for two consecutive periods, not three, as was originally reported.

 

NEW YORK, Aug. 3 (GenomeWeb News) - Bruker BioSciences today said that second-quarter revenue increased 11.3 percent to $71.4 million. The growth included a 3.3 percent favorable currency effect.

 

Despite the year-over-year improvement, the Q2 sales represent the third consecutive sequential quarter in which revenues have fallen. Bruker had fourth quarter 2004 revenue of $85.8 million and first quarter 2005 revenue of $74.9 million.

 

Second-quarter sales in the firm's Bruker Daltonics business, which derives roughly 70 percent of its revenue from life science mass spectrometry systems, grew 7.1 percent to $37.4 million. Sales from Bruker's AXS business, which makes X-ray analysis equipment, swelled 16.4 percent to $34.1 million.

 

The firm's R&D spending rose to $11 million from $10.3 million year over year.

 

Bruker posted second-quarter net earnings of $300,000, or $0 per share, from a net loss of $4.4 million, or $.05 per share, in the same period last year.

 

As of June 30, Bruker listed cash and short-term investments of $92 million.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.